CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV
- CureVac further strengthens its global manufacturing network
- Rentschler Biopharma responsible for manufacturing, downstream processing and formulation of CureVac’s CVnCoV in Laupheim, Germany
- Process optimization currently under way to maximize drug product output
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the companies have initiated the set-up of manufacturing capabilities for CureVac´s COVID-19 vaccine, CVnCoV.